New use of stibene glucoside in preparing medicament for treating Alzheimer disease

Abstract

The invention aims to disclose new use of stibene glucoside in preparing medicament for treating Alzheimer disease. Experiments in which APP695V717I transgenic mouse is used to simulate nerve cell damage in Alzheimer disease prove that pre-administered stibene glucoside can significantly improve behavioral disorders of model mouse by improving brain blood circulation, reducing expression of apoptosis factor Fas / FasL and inhibiting excitatory amino acid level, suggesting that stibene glucoside has distinct protective effect on nerve cell damage in Alzheimer disease. Stibene glucoside prevents and treats Alzheimer disease through multi-target action, stibene glucoside and related adjuvants can be prepared into health products or medicaments for improving cognitive function and treating Alzheimer disease by conventional preparation method. The health products or medicaments can be used for delaying and improving cognitive function and slowing down the progression of Alzheimer disease, and improving physical constitution and life quality of the elderly.

Description

technical field [0001] The present invention relates to a new medical application of stilbene glycosides, in particular to improving cerebral circulation deficiency in Alzheimer's disease and reducing excessive apoptosis factor Fas / FasL in the preparation of drugs for preventing and treating Alzheimer's disease. The expression and the new application of inhibiting the increase of the excitatory amino acid level belong to the field of medicinal chemistry. [0002] Background technique [0003] Stilbene glycoside (2,3,5,4-tetrahydroxy stilbene-2-O-β-D glucoside, Tetrahydroxy Stilbene Glycoside, TSG) belongs to polyhydroxy stilbene compounds, molecular formula is C20H22O9, molecular weight is 406, The molecular structure is as follows: [0004] [0005] Stilbene glycosides are hereinafter referred to as TSG for short, and can be purchased directly in the market, and their content can be analyzed by high performance liquid chromatography. [0006] Alzheimer's disease (AD)...

AI Technical Summary

Problems solved by technology

Experiments have proved that the neurotoxicity of excitatory amino acids has the following links: in Alzheimer's disease, β-amyloid can inhibit the sugar uptake and transport of excitatory amino acids in cultured hippocampal glial cells, thereby producing toxic effects; excessive The excitatory amino acid activates N-methyl-D-aspartate (NMDA) receptors, causing continuous depolarization of excitatory neurons, resulting in changes in ions, osmotic pressure and electrochemistry, which regulate the opening of calcium ion channels , a large influx of extracellular calcium ions leads to overload of intracellular calcium ions, resulting in cell swelling and necrosis; the abnormal release of excitatory amino acids causes pathological long-term potential (LTP) mainly in the hippocampal region, and may cause Impairment of information transmission in the future, forming learning and memory defects

Images